PMS2 and endometrial cancer: One of these patients with endometrial cancer was enrolled based on IHC indicating loss of MLH1/PMS2 and no methylation of MLH1. However, WGS revealed a clear MSS lesion with a msIndel burden of only 0.28 indels/Mb (MSI cut-off: 4 indels/Mb) and low TMB of 3.6 mut/Mb.